Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis is a leading global pharmaceutical company headquartered in Basel, Switzerland. The company focuses on discovering, developing, manufacturing, and marketing prescription pharmaceuticals and eye care products, consistently ranked among the world's top five pharmaceutical companies.
180countries
global presence
76057
employee count
10billion
research investment
Clinical innovation
learning development
Novartis provides comprehensive career development through various learning platforms and professional growth programs. The company offers extensive training through LinkedIn Learning, Coursera, and Skillsoft, providing over 30,500 courses across multiple languages. Their career development approach includes personalized coaching, leadership development programs, and specialized technical training paths.
105000
course completion
47000
active users
10000
skills courses
40
learning languages
These are the expert instructors who will be teaching you throughout the course. With a wealth of knowledge and real-world experience, they’re here to guide, inspire, and support you every step of the way. Get to know the people who will help you reach your learning goals and make the most of your journey.
Director of Preclinical Safety at Novartis
Dr. Alan P. Brown is a Director in Preclinical Safety at Novartis, where he supports therapeutic programs focused on cardiovascular disease. His responsibilities include evaluating compounds for in-licensing and acquisitions, co-chairing a liver safety advisory team, and conducting educational workshops for colleagues at Novartis. Dr. Brown holds a Bachelor of Science in microbiology from the University of Michigan and a Ph.D. in pharmacology and toxicology from the University of Arizona. He completed postdoctoral research at Michigan State University and is a Diplomate of the American Board of Toxicology. With extensive experience in the pharmaceutical industry, he plays a vital role in ensuring the safety and efficacy of new therapeutic compounds.
Associate Director of Discovery Sciences at Novartis
Dr. Douglas S. Auld serves as the Associate Director of Discovery Sciences in Biomedical Research at Novartis, where he focuses on advancing therapeutic programs. He earned his Ph.D. in Chemistry from the University of North Carolina under the guidance of Professor Gary J. Pielak and completed postdoctoral training at MIT with Professor Paul Schimmel. Dr. Auld played a pivotal role in establishing Pharmacopeia, a company that utilized combinatorial chemistry and ultra-high-throughput screening (HTS) to facilitate drug discovery. In 2004, he was instrumental in launching the NIH Chemical Genomics Center (NCGC), where he contributed to its development into a center of scientific excellence and received the NIH Merit Award for his leadership in 2006. Since joining Novartis in 2010, Dr. Auld's lab has provided assay development expertise and innovative technologies to support drug development efforts, and he has authored over 110 scientific publications while lecturing internationally on his research.